Search

Objective(s): Central nervous system demyelination is the main feature of multiple sclerosis (MS). The most important unmet need in MS is use of treatments that delay the progression of the disease. Leucine-rich repeat and Immunoglobulin-like domain containing NOGO receptor-interacting protein 1(LINGO-1) have been known as inhibitors of oligodendrocyte differentiation and myelination. Materials and Methods: We investigated LINGO-1 antibody effects on remyelination and neurobehavioral deficit using cuprizone-induced demyelination. Animals were randomly divided into three groups (n = 10): (1) Control group; received the regular diet, (2) CPZ group; normal saline was injected intraperitoneally, and (3) Treatment group; LINGO-1 antibody (10 mg/kg) was injected IP once every six days for 3 weeks. We assessed the level of myelin basic protein (MBP), neurofilament heavy chain (NF200), and Brain-derived neuroprotective factor (BDNF) in the corpus callosum (CC) by immunostaining against MBP, NF200, and BDNF. Results: We found decreased levels of MBP, NF200, and BDNF in demyelinated CC, and anti-LINGO-1 treatment improved demyelinated structures. Furthermore, motor impairment was measured by Open-field (OFT) and Balance beam tests. In the treatment group, motor impairment was significantly improved. Conclusion: These results provide evidence that LINGO-1 antibody can improve remyelination and neurobehavioral deficit.

Background and aims Chronic obstructive pulmonary disease (COPD) is a progressive process that leading to major clinical problems in patients. There is no highly effective treatment for these patients and therapists only try to relieve the symptoms. But, there are interventions such as self-management program for improvement of health level in patients. 5A model, known as behavior change counseling model is an evidence-based approach for behavior change and self-management. Thus this study was performed to investigate the effects of self-management program based on 5A model on some of clinical parameters in COPD patients. Methods this clinical trial was performed on 50 COPD patients that referred to Apadana sub-special clinic in Ahvaz. Patients were randomly assigned to control and intervention groups. The control group received usual care and the intervention group received usual care plus a self-management program based on the 5A model (includes: Assess Advise, Agree, Assist and Arrange stage). Patients were assessed by six-minute walking test and the Borg scale for exercise tolerance level and dyspnea severity at baseline and after 3 months. Chi-square and t-test in the SPSS software were used to data analysis. Results There was no significant difference between the groups in exercise tolerance at base line; but, they were significantly different at the end of 3 months (P=0.007). In addition, a significant reduction was found in patients' dyspnea in the intervention group, compared with the control group after 3 months (P